Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients
with urothelial cancer that has not responded to previous treatment and has spread to other
places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, may
interfere with the ability of tumor cells to grow and spread. Giving paclitaxel together with
pembrolizumab may be an effective treatment for urothelial cancer.